BioSpace News Archive

Arbutus Biopharma Corporation today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 25th Annual Global Investment Conference, being held at the Lotte New York Palace Hotel, in New York City on September 11 - 13, 2023.

Genprex, Inc. today announced that its Chief Financial Officer, Ryan Confer, will be providing an overview of the Company’s gene therapies for cancer and diabetes at the upcoming H.C. Wainwright 25th Annual Global Investment Conference.

ProQR Therapeutics NV. today announced that Company management will participate in the HC Wainwright 25th Annual Global Investment Conference.

Avalyn Pharma Inc. announced that Dr. Nazia Chaudhuri will be presenting data from Avalyn’s Phase 1b ATLAS study showing the positive impact of AP01 (inhaled pirfenidone) on the forced vital capacity (FVC) of adults with idiopathic pulmonary fibrosis compared to historical controls.

Praxis Precision Medicines , Inc. today announced that management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 12 p.m. EDT.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced it has completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the manufacturing, preclinical and clinical development plan for ART26.12.

INOVIO today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP).

Intensity Therapeutics, Inc. today announced that the US Food and Drug Administration’s Office of Orphan Products Development has granted orphan-drug designation for the treatment of soft tissue sarcoma (STS) to the three active moieties comprising INT230-6, cisplatin, vinblastine sulfate, and the diffusion enhancer SHAO-FA (8-((2-hydroxybenzoyl) amino)octanoate).

Shape Memory Medical Inc announced that the Food and Drug Administration (FDA) granted investigational device exemption (IDE) for the company to begin a prospective, multicenter, randomized, open-label trial to determine safety and effectiveness of the IMPEDE-FX RapidFill® Device to improve abdominal aortic aneurysm (AAA) sac behavior when used with elective endovascular aneurysm repair (EVAR).